Theravance Biopharma Inc

TBPH | NASDAQ

Price Alert Chart Builder DCF Calculator

$17.08

+$0.03 (+0.18%)

Sep 22, 2026, 11:40 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $883.67M

Enterprise Value $551.56M

Beta 0.17

Average Volume 559.43K

Shares Outstanding (Diluted) 51.67M

Shares Change YoY 1.86%

Institutional Ownership 97.82%

Exchange NASDAQ

ISIN KYG8807B1068

Price Performance

Price Change 1M 0.2%

Price Change 3M 0.5%

Price Change 6M 11.5%

Price Change YTD -6.1%

Price Change 1Y 21.2%

Price Change 3Y 87.2%

Price Change 5Y 142.9%

1M CAGR (ann.) 0.7%

1Y CAGR (ann.) 17.8%

5Y CAGR (ann.) 14.6%

All-Time CAGR -2.4%

Valuation

PE Ratio 16.88

Forward PE 9.20

PEG Ratio 0.05

Forward PEG -0.45

PS Ratio 8.47

Forward PS 8.50

PB Ratio 3.05

P/FCF Ratio 17.05

P/Adj. FCF Ratio 27.39

P/OCF Ratio 17.05

EV/Sales 5.29

EV/EBIT 9.18

EV/EBITDA 8.78

EV/FCF 10.64

Earnings Yield 5.9%

FCF Yield 5.9%

Adj. FCF Yield 3.6%

Financial Health

Net Cash $332.11M

Total Debt $55.55M

Cash & Short-Term Investments $387.66M

Total Assets $469.77M

Current Ratio 13.54

Quick Ratio 13.54

Debt / Equity Ratio 0.13

Debt / EBITDA 0.88

Debt / FCF 1.07

OCF / Debt 0.93

Interest Coverage 4.03

Altman Z-Score 1.98

Piotroski F-Score 6

Margins & Profitability

Gross Profit Margin 89.4%

Operating Profit Margin -2.9%

EBITDA Margin 65.6%

Net Profit Margin 51.6%

FCF Margin 49.7%

Adj. FCF Margin 30.9%

SBC / Revenue 18.7%

SBC Impact (per share) -37.7%

Returns

Return on Assets 11.4%

Return on Equity 19.4%

Return on Invested Capital 0.9%

Return on Capital Employed 1.1%

Return on Tangible Assets 11.4%

Historical Growth (CAGR)

Revenue CAGR 3Y 26.7%

Revenue CAGR 5Y 10.2%

Revenue CAGR 10Y 10.5%

EPS CAGR 3Y -55.3%

EPS CAGR 5Y -30.8%

EPS CAGR 10Y 76.9%

FCF CAGR 3Y 32.1%

FCF CAGR 5Y 2539.8%

FCF CAGR 10Y 34.5%

Analyst Forecasts

Analyst Rating Hold

Analyst Count 17

EPS Growth Next 3Y 14.0%

Revenue Growth Next 3Y 0.9%

Earnings Date Nov 9, 2026

EPS Estimate (next Q) $0.24

EPS Growth Est (next Q) 500.0%

Revenue Est (next Q) $21.95M

Revenue Growth Est (next Q) 9.8%

Fair Value Estimates

Graham Number $11.29

Graham Upside -33.8%

Lynch Fair Value $5.05

Lynch Upside -70.4%

Price Target $17

Price Target Upside -0.3%

Cash Flow

Operating Cash Flow $51.83M

Free Cash Flow $51.82M

Adj. Free Cash Flow $32.27M

FCF Per Share $1

OCF Per Share $1

OCF/S Ratio 49.7%

Income Statement

Revenue $104.31M

Gross Profit $94.69M

Operating Income $-3.02M

EBITDA $62.83M

Net Income $53.81M

EPS (Diluted) $1.01

Revenue / Employee $1.16M

Profit / Employee $597.87K

Employees 90